Alkem Laboratories has received approval from board of directors for transfer of the trade generics business of the Company as a going concern, on a slump sale basis, to M/s. Alkem Wellness, a wholly owned subsidiary of the Company, incorporated in India. The transaction is proposed to be effected through a business transfer agreement and will be effective on or before April 01, 2025 or such other date as may be mutually agreed between the parties, subject to customary closing conditions.
The Board of Directors of Alkem Laboratories at its meeting held on December 10, 2024 has approved the same.
Alkem Laboratories is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.
